Press Room

DCAT Week 2023

Start
Monday, March 20, 2023 - 09:00
End
Thursday, March 23, 2023 - 18:00
Location: New York, United States

Meet us at the DCAT Week and schedule a meeting now with our key experts at The Lexington Hotel.

Schedule a meeting button | Hovione

 

 

Learn how Hovione can support your projects and the production of your much needed medicines and breakthrough therapies.

 

You might be interested in:

Continuous Tableting for your drug product. The future is continuous | Hovione
Continuous tableting is suited for all types of drug products for oral delivery, and allows for leaner and risk-reduced development paths, leaner supply chains, increased built-in quality, and more flexible and less complex manufacturing processes. Meet our team and find out why The future is continuous.

 

Dispersome® Learn more about the innovative technology capable of solving the poor solubility issues of your drug candidate | Hovione

Dispersome® technology enables the formulation of API with a novel protein-based excipient, developing ASDs with high solubility and bioavailability which can be manufactured at a large-scale using Spray Drying. If you are developing a novel drug formulation or need to improve your drug candidate, speak with our team.

 

Let’s discuss your project together.

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026